Back to Search Start Over

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Authors :
Jun Toyohara
Mohammed Al-Qahtani
Ya-Yao Huang
Emiliano Cazzola
Sergio Todde
Shozo Furumoto
Renata Mikolajczak
Clemens Decristoforo
Nic Gillings
Min Yang
Raymond Reilly
Adriano Duatti
Antonia Denkova
Ralf Schirrmacher
Giuseppe Carlucci
Yann Seimbille
Zhaofei Liu
Beverley Ellis
Bart T. Cornelissen
Klaus Kopka
Emerson Bernardes
University of Coimbra [Portugal] (UC)
University Medical Center Groningen [Groningen] (UMCG)
IRCCS Sacro Cuore Don Calabria Hospital [Vérone, Italie]
Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven)
Technische Universiteit Delft (TU Delft)
University of Wisconsin-Madison
Nuclear Oncology (CRCINA-ÉQUIPE 13)
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE)
Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE)
Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)
Rigshospitalet [Copenhagen]
Copenhagen University Hospital
Netherlands Cancer Institute (NKI)
Antoni van Leeuwenhoek Hospital
International Atomic Energy Agency [Vienna] (IAEA)
Paul Scherrer Institute (PSI)
Radioisotope Centre POLATOM [Otwock, Pologne] (POLATOM)
Helmholtz-Zentrum Dresden-Rossendorf (HZDR)
DDRC SRL Diagnostics [Kerala, India] (Molecular Group of Companies)
University of Toronto
Stellenbosch University
Erasmus University Medical Center [Rotterdam] (Erasmus MC)
Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
University of Groningen [Groningen]
National Institutes of Health [Bethesda] (NIH)
Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Bernardo, Elizabeth
Source :
Repositório Científico de Acesso Aberto de Portugal, Repositório Científico de Acesso Aberto de Portugal (RCAAP), instacron:RCAAP, European Association of Nuclear Medicine, issuing body-EJNMMI radiopharmacy and chemistry, European Association of Nuclear Medicine, issuing body-EJNMMI radiopharmacy and chemistry, London : Springer Open, [2016]-, 2021, 6, pp.31. ⟨10.1186/s41181-021-00146-9⟩, EJNMMI Radiopharmacy and Chemistry 6(2021)1, 31, EJNMMI Radiopharmacy and Chemistry 7(2022)1, 25, EJNMMI Radiopharmacy and Chemistry, Vol 6, Iss 1, Pp 1-16 (2021), EJNMMI Radiopharmacy and Chemistry 8(2023), 6, EJNMMI Radiopharmacy and Chemistry, European Association of Nuclear Medicine, issuing body-EJNMMI radiopharmacy and chemistry, 2021, 6, pp.31. ⟨10.1186/s41181-021-00146-9⟩
Publication Year :
2021
Publisher :
SPRINGERNATURE, 2021.

Abstract

Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Main Body This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals. Conclusion Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field, and include new PET-labelling methods for 11C and 18F, the importance of choosing the proper chelator for a given radioactive metal ion, implications of total body PET on use of radiopharmaceuticals, legislation issues and radionuclide therapy including the emerging role of 161Tb.

Details

Language :
English
ISSN :
2365421X
Database :
OpenAIRE
Journal :
Repositório Científico de Acesso Aberto de Portugal, Repositório Científico de Acesso Aberto de Portugal (RCAAP), instacron:RCAAP, European Association of Nuclear Medicine, issuing body-EJNMMI radiopharmacy and chemistry, European Association of Nuclear Medicine, issuing body-EJNMMI radiopharmacy and chemistry, London : Springer Open, [2016]-, 2021, 6, pp.31. ⟨10.1186/s41181-021-00146-9⟩, EJNMMI Radiopharmacy and Chemistry 6(2021)1, 31, EJNMMI Radiopharmacy and Chemistry 7(2022)1, 25, EJNMMI Radiopharmacy and Chemistry, Vol 6, Iss 1, Pp 1-16 (2021), EJNMMI Radiopharmacy and Chemistry 8(2023), 6, EJNMMI Radiopharmacy and Chemistry, European Association of Nuclear Medicine, issuing body-EJNMMI radiopharmacy and chemistry, 2021, 6, pp.31. ⟨10.1186/s41181-021-00146-9⟩
Accession number :
edsair.doi.dedup.....a1e914773cb75478d4e90efd9ebe2f51
Full Text :
https://doi.org/10.1186/s41181-021-00146-9⟩